Delving into the Latest Updates on Pentetreotide with Synapse

Overview

Basic Info

Drug Type

Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals

Synonyms

111In-octreotid, 111In-octreotide, 111In-oktreotid

+ [15]

Target

SSTR

Mechanism

SSTR antagonists(Somatostatin receptor antagonists), SPECT(Single-photon emission-computed tomography enhancers)

Therapeutic Areas

NeoplasmsNervous System DiseasesRespiratory Diseases+ [2]

Active Indication

Breast CancerCentral Nervous System NeoplasmsSmall Cell Lung Cancer+ [2]

Inactive Indication-

Originator Organization

Louisiana State University

Active Organization

Pharm SintezCurium US Holdings LLCPDRadiopharma, Inc.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

CZ (01 Feb 1994),

Diagnostic agents

RegulationOrphan Drug (US)

Login to view First Approval Timeline

Structure

Molecular FormulaC63H84InN13O19S2

InChIKeyONJXCGCIKIYAPL-MLRSDOHDSA-K

CAS Registry139096-04-1

Gene Sequence

Sequence Code 526024272

TERAVECT is a phase III randomized study of patients with digestive neuroendocrine tumors after complete surgical resection of liver metastases treated with In111-Pentetreotide-based adjuvant radiotherapy.
In this study, targeted radionuclide therapy is used at an earlier stage of the disease.The objective is to target residual tumor cells and/or micrometastases which escaped surgical resection. Given the poor prognosis associated with recurrence, this treatment should prevent relapse.

Start Date01 Sep 2015

Sponsor / Collaborator-

JPRN-UMIN000010183 / CompletedIIT

Diagnosis for the patients with neuroendocrine tumor by 111In-DTPA-octreotide - Diagnosis of NET by OctreoScan

Start Date06 Mar 2013

Sponsor / Collaborator-

100 Clinical Results associated with Pentetreotide

Login to view more data

100 Translational Medicine associated with Pentetreotide

Login to view more data

100 Patents (Medical) associated with Pentetreotide

Login to view more data

875

Literatures (Medical) associated with Pentetreotide

01 May 2024·Japanese Journal of Radiology

Combined visual and quantitative assessment of somatostatin receptor scintigraphy for staging and restaging of neuroendocrine tumors

Article

Author: Ikemitsu, Daiki ; Takayama, Tetsuji ; Otomi, Yoichi ; Okada, Yasuyuki ; Kasai, Ryosuke ; Azane, Shota ; Otani, Tamaki ; Matsuda, Noritake ; Kunikane, Yamato ; Ueki, Yuya ; Otsuka, Hideki ; Harada, Masafumi ; Bando, Takanori

PURPOSESomatostatin receptor scintigraphy (SRS) using ¹¹¹In-DTPA-DPhe¹-octreotide (pentetreotide) has become an integral part of neuroendocrine neoplasm management. The lack of precise quantification is a disadvantage of SRS. This study aimed to adapt the standardized uptake value (SUV) to SRS, establish the SUV range for physiological uptake in the liver, kidney, and spleen, and elucidate the utility of combined visual and quantitative SRS assessment for staging and restaging of neuroendocrine tumors (NETs).MATERIALS AND METHODSThis study included 21 patients with NETs who underwent ¹¹¹In-pentetreotide SRS. The SUV of physiological and pathological uptake was calculated using bone single-photon emission computed tomography (SPECT) quantitative analysis software (GI-BONE). For visual analysis, the primary and metastatic lesions were scored visually on planar and SPECT images using a five-point scale. We assessed the relationships between the SUVs of the liver, kidney, and spleen in the dual phase, and among quantitative indices, visual score, and pathological lesions classification.RESULTSSixty-three NEN lesions were evaluated. The mean ± standard deviation maximum SUVs (SUVmax) were liver: 4 h, 2.6 ± 1.0; 24 h, 2.2 ± 1.0; kidney: 4 h, 8.9 ± 1.8; 24 h, 7.0 ± 2.0; and spleen; 4 h, 11.3 ± 4.5; 24 h, 11.5 ± 7.6. Higher SUVmax was significantly associated with higher visual scores on dual-phase SPECT (4 h, p < 0.001; 24 h, p < 0.001) (4 h: scores 3 and 4, p < 0.05; scores 3 and 5: p < 0.01; scores 4 and 5: p < 0.01; 24 h: scores 3 and 4, p = 0.0748; scores 3 and 5: p < 0.01; scores 4 and 5: p < 0.01).CONCLUSIONWe adapted the SUV to SRS and established the range of SUV for physiological uptake in the liver, kidney, and spleen. Combined visual and quantitative assessment is useful for imaging individual lesions in greater detail, and may serve as a new tumor marker of SRS for staging and restaging of NETs.

01 Jan 2024·Endocrinology, Diabetes & Metabolism Case Reports

FSH-producing pituitary neuroendocrine tumor as a cause of ovarian hyperstimulation syndrome

Article

Author: Moriyoshi, Koki ; Kitamura, Takuya ; Nanba, Kazutaka ; Doi, Kento ; Abiko, Kaoru ; Kishimoto, Naoya ; Tagami, Tetsuya ; Inoshita, Naoko ; Kuwahara, Ryo

SummaryFunctioning gonadotroph tumors are rare neoplasms that can cause ovarian hyperstimulation syndrome (OHSS) in women of reproductive age. Here, we present a case of a follicle-stimulating hormone (FSH)-producing pituitary neuroendocrine tumor (PitNET) with irregular menstrual cycles and OHSS in a Japanese woman. A 34-year-old woman with bilateral multi-cystic ovarian mass was referred to our hospital for ovarian surgery. The imaging feature of magnetic resonance imaging (MRI) of the ovary and elevated estradiol levels with normal FSH and low luteinizing hormone (LH) levels led us to suspect the presence of a functioning gonadotroph PitNET. MRI revealed a 19-mm pituitary tumor, and increased tracer uptake was observed in the pituitary lesion on 111In-pentetreotide scintigraphy. Transsphenoidal tumor resection resulted in the resolution of the ovarian enlargement, normalization of her menstrual cycles, and spontaneous pregnancy. Immunohistochemistry (IHC) of the resected tumor for pituitary transcription factors, including steroidogenesis factor 1 (SF1) and estrogen receptor alpha, demonstrated positive immunoreactivity, whereas IHC for pituitary-specific positive transcription factor 1 was negative, suggesting that the tumor belonged to the SF1 lineage of PitNETs (gonadotroph tumor). The tumor cells showed positive expression of FSHβ, while LHβ was mostly negative. Consistent with the high pituitary tumor uptake observed on 111In-pentetreotide scintigraphy, the pituitary tumor showed positive expression of somatostatin receptor 2A. Detailed clinical and histological evaluations will provide useful information to understand these rare functioning gonadotroph tumors better.Learning points

Functioning gonadotroph tumors are very rare neuroendocrine tumors of pituitary origin.

Women of reproductive age presenting with bilateral multi-cystic ovarian enlargement, irregular menstrual cycles, and hyperestrogenemia under unsuppressed follicle-stimulating hormone (FSH) levels should be evaluated for FSH-producing tumor.

Raising awareness of OHSS due to functioning gonadotroph tumors is crucial to prevent unnecessary ovarian surgery.

Comprehensive histological analysis may provide useful information to better understand the characteristics of functioning gonadotroph tumors.

09 Aug 2023·Diagnostics (Basel, Switzerland)

Radio-Guided Lung Surgery: A Feasible Approach for a Cancer Precision Medicine.

Review

Author: Frantellizzi, Viviana ; Filippi, Luca ; Tomaciello, Miriam ; Marampon, Francesco ; Evangelista, Laura ; De Feo, Maria Silvia ; Conte, Miriam ; De Vincentis, Giuseppe

BACKGROUNDRadio-guided surgery is a reliable approach used for localizing ground-glass opacities, lung nodules, and metastatic lymph nodes. Lung nodules, lymph node metastatic involvement, and ground-glass opacities often represent a challenge for surgical management and clinical work-up.METHODSPubMed research was conducted from January 1997 to June 2023 using the keywords "radioguided surgery and lung cancer".RESULTSDifferent studies were conducted with different tracers: technetium-99m-albumin macroaggregates, cyanoacrylate combined to technetium-99m-sulfur colloid, indium-111-pentetreotide, and fluorine-18-deoxyglucose. A study proposed naphthalocyanine radio-labeled with copper-64. Radio-guided surgery has been demonstrated to be a reliable approach in localizing a lesion, and has a low radiological burden for personnel exposure and low morbidity. The lack of necessity to conduct radio-guided surgery under fluoroscopy or echography makes this radio-guided surgery an easy way of performing precise surgical procedures.CONCLUSIONSRadio-guided surgery is a feasible approach useful for the intraoperative localization of ground-glass opacities, lung nodules, and metastatic lymph nodes. It is a valid alternative to the existing approaches due to its low cost, associated low morbidity, the possibility to perform the procedure after several hours, the low radiation dose applied, and the small amount of time that is required to perform it.

100 Deals associated with Pentetreotide

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	V09IB01	DB11835

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Breast Cancer	RU	Pharm Sintez	01 Jan 2007
Central Nervous System Neoplasms	RU	Pharm Sintez	01 Jan 2007
Small Cell Lung Cancer	RU	Pharm Sintez	01 Jan 2007
Neuroendocrine Tumors	US	Curium US Holdings LLC	02 Jun 1994
Diagnostic agents	CZ	-	01 Feb 1994

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2007	Not Applicable	Neuroendocrine Tumors	18	Multiple 500 mCi doses of 111In-pentetreotide	bngwvydrcx(wdbyuvbcdl) = gmfyvwvspy cvesoypmrb (gljddaqwpt )	-	20 Jun 2007
ASCO2004	Not Applicable	Neoplasms	85	In-111 pentetreotide	(tqnqstkjdj) = rievtclsfs pnrlpkrftu (fgdxzleqby )	-	15 Jul 2004
NCT02546388 (CTgov)	Not Applicable	Cardiac sarcoidosis	17	Gallium-68 DOTATATE (Gallium-68 DOTATATE)	czusfsgoec(zojwmfdglf) = fvzvmhnvrk pcsevsmwxe (ouacowzppf, jusbvowfid - vftkbqhsce) View more	-	25 Mar 2020
NCT02546388 (CTgov)	Not Applicable	Cardiac sarcoidosis	17	Indium-111 Pentreotide (Indium-111 Pentreotide (OctreoScan))	czusfsgoec(zojwmfdglf) = nfzaqcdjed pcsevsmwxe (ouacowzppf, xuuiiqhnmq - zdaqgapund) View more	-	25 Mar 2020
ARVO2004	Not Applicable	-	-	111 Indium pentetreotide	(xgazgxnllt) = rtlzlnilsd pvnehfgnfm (kuousyvtcx )	-	01 May 2004
ARVO2004	Not Applicable	-	-	125 I somatostatin-14	(xgazgxnllt) = nitkzhnvug pvnehfgnfm (kuousyvtcx )	-	01 May 2004
ASCO2010	Not Applicable	Neuroendocrine Tumors	83	500 mCi doses of <sup>111</sup>In-pentetreotide	(fyiuvamrqz) = uukehyqwiv ybabaecwrl (fiexqhaiyi )	Positive	20 May 2010